| Acute lymphocytic leukemia
Asparlas vs Xatmep
Side-by-side clinical, coverage, and cost comparison for acute lymphocytic leukemia.Deep comparison between: Asparlas vs Xatmep with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXatmep has a higher rate of injection site reactions vs Asparlas based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xatmep but not Asparlas, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Asparlas
Xatmep
At A Glance
IV infusion
Every 21 days
Pegylated L-asparaginase
Oral
Once weekly
Folate analog metabolic inhibitor
Indications
- Acute lymphocytic leukemia
- Acute lymphocytic leukemia
- Juvenile polyarthritis
Dosing
Acute lymphocytic leukemia 2,500 units/m2 intravenously no more frequently than every 21 days.
Acute lymphocytic leukemia 20 mg/m2 given one time weekly as part of a multi-agent combination chemotherapy maintenance regimen, oral.
Juvenile polyarthritis Starting dose of 10 mg/m2 given one time weekly, oral; titrate gradually to achieve optimal response, up to 30 mg/m2/week in pediatric patients.
Contraindications
- History of serious hypersensitivity reactions, including anaphylaxis, to pegylated L-asparaginase therapy
- History of serious pancreatitis during previous L-asparaginase therapy
- History of serious thrombosis during previous L-asparaginase therapy
- History of serious hemorrhagic events during previous L-asparaginase therapy
- Severe hepatic impairment
- Pregnancy in patients with non-malignant diseases
- Severe hypersensitivity to methotrexate
Adverse Reactions
Most common Elevated transaminase, bilirubin increased, pancreatitis, abnormal clotting studies, diarrhea, hypersensitivity, embolic and thrombotic events, sepsis, dyspnea, hemorrhages, fungal infection, pneumonia, arrhythmia, cardiac failure
Serious Hypersensitivity, pancreatitis, thrombosis, hemorrhage, hepatotoxicity including veno-occlusive disease
Postmarketing Veno-occlusive disease (hepatic)
Most common Ulcerative stomatitis, leukopenia, nausea, abdominal distress, malaise, fatigue, chills, fever, dizziness, decreased resistance to infection
Serious Bone marrow suppression, serious infections, renal toxicity, gastrointestinal toxicity, hepatic toxicity, pulmonary toxicity, hypersensitivity and dermatologic reactions, secondary malignancies, infertility
Postmarketing Pancytopenia, aplastic anemia, thromboembolic events, hepatotoxicity, cirrhosis, fatal opportunistic infections (including Pneumocystis jiroveci pneumonia), leukoencephalopathy, Stevens-Johnson syndrome, toxic epidermal necrolysis, pulmonary fibrosis
Pharmacology
Pegylated L-asparaginase enzyme that depletes plasma asparagine by catalyzing its conversion to aspartic acid and ammonia; leukemic cells with low asparagine synthetase expression depend on exogenous asparagine for survival and are killed by its depletion.
Methotrexate inhibits dihydrofolic acid reductase, interfering with DNA synthesis, repair, and cellular replication by blocking reduction of dihydrofolates to tetrahydrofolates required for purine nucleotide and thymidylate synthesis; the mechanism in pJIA is unknown but may affect immune function.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Asparlas
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Xatmep
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (2/12) · Qty limit (0/12)
UnitedHealthcare
Asparlas
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Xatmep
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Asparlas
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Xatmep
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Asparlas Patient Assistance ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Xatmep.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AsparlasView full Asparlas profile
XatmepView full Xatmep profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.